Redeye maintains a positive view of Transtema despite a weak Q1 and cuts in Base Case and forecasts.
Redeye retains its positive stance towards Hanza despite a softer Q1 report than expected, resulting...
Sprint Bioscience recorded sales improved to SEK 17.
Redeye leave its comments on Xbrane following the announcement of a USD45m deal plus royalties for X...
Redeye gives its preview on OssDsign’s Q1 2024 report, due on May 14.
Administer’s profitability in Q1 improved more than expected, and our 2024E EBITDA estimate is up by...
Etteplan's Q1 results were largely as expected, with slight earnings miss vs.
Redeye provides a research update following the Q1 report published by Initiator Pharma earlier toda...
Group net sales was EUR 28m in Q1 (Nordea est. EUR 29m) meanwhile adjusted EBITDA was EUR 13m (Norde...
Redeye sees a quarter well in line with our estimates, and we believe that the quarterly reports wil...
Redeye updated its estimates after reviewing Fantasma Games’ Q1 report, which came in stronger than ...
Redeye updates on Invisio following its Q1-results which were in line with our expectations.
This year could turn out to be better than expected for Incap.
Ferronordic will report its Q1 results on 16 May. Taken together, we expect another challenging quar...
Investors House reported Q1 2024 revenue of EUR 1.6m, 4% below our estimate, while net operating inc...
Redeye remains positive towards Avensia following a Q1 report largely matching our forecasts.
Q1 EBITA +16% y-o-y while peers decline, 8.9% (7.9%) margin Strong start in weakened market increase...
80% of the ATH order book to be delivered within 12 months Higher opex to cut EBIT by 5-7% in 2024e-...
Mixed demand between US (better) and Europe (weaker) Recruitment market has improved, and could lead...
Q1 report due Wednesday 15 May at 07:00 CEST Q1e: sales EUR 44.
